Cogent Biosciences, Inc.
Cogent Biosciences, Inc. (COGT) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · COGT · as of Jun 8, 2026
Activity summary
Buy transactions
1
P-Purchase only
Sell transactions
6
12 Months
Buy/Sell ratio
0.17
Buy/Sell (by trades)
Overall sentiment
Cogent Biosciences, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
COGT insider buying and selling by quarter
COGT insider selling · COGT insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · COGT ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
COGT executive sell shares · COGT board member insider trading · COGT insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| May 19, 2026 | Robbins Andrew R President and CEO · Director | Gift | 160,000 | — | Form 4 |
| May 19, 2026 | Robbins Andrew R President and CEO · Director | Gift | 160,000 | — | Form 4 |
| Mar 31, 2026 | Fairmount Funds Management LLC Director | Other | 7,000,000 | — | Form 4 |
| Mar 31, 2026 | Fairmount Funds Management LLC Director | Sale | 7,000,000 | $242.62M⚡ | Form 4 |
| Jan 22, 2026 | Fairmount Funds Management LLC Director | Sale | 3,500,000 | $127.40M⚡ | Form 4 |
| Dec 26, 2025 | Kearns Evan Chief Legal Officer | Sale | 65,000 | $2.52M⚡ | Form 4 |
| Dec 26, 2025 | Green John L. CFO | Sale | 77,000 | $2.98M⚡ | Form 4 |
| Dec 26, 2025 | Sachs Jessica Chief Medical Officer | Sale | 82,642 | $3.20M⚡ | Form 4 |
| Dec 26, 2025 | Robinson John Edward Chief Scientific Officer | Sale | 90,000 | $3.49M⚡ | Form 4 |
| Dec 17, 2025 | Robinson John Edward Chief Scientific Officer | Award | 320,000 | — | Form 4 |
| Dec 17, 2025 | Robinson John Edward Chief Scientific Officer | Other | 139,998 | $5.52M⚡ | Form 4 |
| Dec 17, 2025 | Robinson John Edward Chief Scientific Officer | Award | 50,000 | — | Form 4 |
| Dec 17, 2025 | Robbins Andrew R President and CEO · Director | Award | 840,000 | — | Form 4 |
| Dec 17, 2025 | Robbins Andrew R President and CEO · Director | Other | 367,497 | $14.50M⚡ | Form 4 |
| Dec 17, 2025 | Robbins Andrew R President and CEO · Director | Award | 185,000 | — | Form 4 |
| Dec 17, 2025 | Pinnow Cole Chief Commercial Officer | Award | 214,000 | — | Form 4 |
| Dec 17, 2025 | Pinnow Cole Chief Commercial Officer | Other | 94,800 | $3.74M⚡ | Form 4 |
| Dec 17, 2025 | Pinnow Cole Chief Commercial Officer | Award | 50,000 | — | Form 4 |
| Dec 17, 2025 | Kearns Evan Chief Legal Officer | Award | 260,000 | — | Form 4 |
| Dec 17, 2025 | Kearns Evan Chief Legal Officer | Other | 125,602 | $4.95M⚡ | Form 4 |
| Dec 17, 2025 | Kearns Evan Chief Legal Officer | Award | 40,000 | — | Form 4 |
| Dec 17, 2025 | Sachs Jessica Chief Medical Officer | Award | 320,000 | — | Form 4 |
| Dec 17, 2025 | Sachs Jessica Chief Medical Officer | Other | 154,716 | $6.10M⚡ | Form 4 |
| Dec 17, 2025 | Sachs Jessica Chief Medical Officer | Award | 50,000 | — | Form 4 |
| Dec 17, 2025 | Green John L. CFO | Award | 300,000 | — | Form 4 |
Robbins Andrew R
President and CEO · Director
Date
May 19
Shares
160,000
Price
—
Value
—
Robbins Andrew R
President and CEO · Director
Date
May 19
Shares
160,000
Price
—
Value
—
Fairmount Funds Management LLC
Director
Date
Mar 31
Shares
7,000,000
Price
—
Value
—
Fairmount Funds Management LLC
Director
Date
Mar 31
Shares
7,000,000
Price
$34.66
Value
$242.62M ⚡
Fairmount Funds Management LLC
Director
Date
Jan 22
Shares
3,500,000
Price
$36.40
Value
$127.40M ⚡
Kearns Evan
Chief Legal Officer
Date
Dec 26
Shares
65,000
Price
$38.70
Value
$2.52M ⚡
Sachs Jessica
Chief Medical Officer
Date
Dec 26
Shares
82,642
Price
$38.70
Value
$3.20M ⚡
Robinson John Edward
Chief Scientific Officer
Date
Dec 26
Shares
90,000
Price
$38.74
Value
$3.49M ⚡
Robinson John Edward
Chief Scientific Officer
Date
Dec 17
Shares
320,000
Price
—
Value
—
Robinson John Edward
Chief Scientific Officer
Date
Dec 17
Shares
139,998
Price
$39.45
Value
$5.52M ⚡
Robinson John Edward
Chief Scientific Officer
Date
Dec 17
Shares
50,000
Price
—
Value
—
Robbins Andrew R
President and CEO · Director
Date
Dec 17
Shares
840,000
Price
—
Value
—
Robbins Andrew R
President and CEO · Director
Date
Dec 17
Shares
367,497
Price
$39.45
Value
$14.50M ⚡
Robbins Andrew R
President and CEO · Director
Date
Dec 17
Shares
185,000
Price
—
Value
—
Pinnow Cole
Chief Commercial Officer
Date
Dec 17
Shares
94,800
Price
$39.45
Value
$3.74M ⚡
Kearns Evan
Chief Legal Officer
Date
Dec 17
Shares
125,602
Price
$39.45
Value
$4.95M ⚡
Sachs Jessica
Chief Medical Officer
Date
Dec 17
Shares
154,716
Price
$39.45
Value
$6.10M ⚡
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About COGT insider trading
COGT insider trades
Cogent Biosciences, Inc. (COGT) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Robbins Andrew R (President and CEO · Director), Fairmount Funds Management LLC (Director), Kearns Evan (Chief Legal Officer). Over the past 12 months, 5 insiders have filed transactions with the SEC. COGT insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Cogent Biosciences, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
COGT insider trading · 5 questionsThe insiders of Cogent Biosciences, Inc. (COGT) include executives and directors such as Robbins Andrew R (President and CEO · Director), Fairmount Funds Management LLC (Director), Kearns Evan (Chief Legal Officer), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026